Evidence map›Paper›PMID 42551467›Full record

ArticleHuman vaccines & immunotherapeutics2026

Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents.

Olajide J Olagunju, Oladayo A Oyebanji, Debbie Keresztesy, Dennis Wilk, Evan Dickerson, Tiffany Wallace, Laurel Holland, Mike Payne, Ellen See, Chia Jung Li and 9 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Olajide J OlagunjuDivision of Infectious Diseases and HIV Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Oladayo A OyebanjiDivision of Infectious Diseases and HIV Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Debbie KeresztesyDivision of Infectious Diseases and HIV Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Dennis WilkDivision of Infectious Diseases and HIV Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Evan DickersonDivision of Geriatrics and Palliative Medicine, Rhode Island Hospital, Brown University Health, Providence, RI, USA.
Tiffany WallaceDivision of Geriatrics and Palliative Medicine, Rhode Island Hospital, Brown University Health, Providence, RI, USA.
Laurel HollandDivision of Geriatrics and Palliative Medicine, Rhode Island Hospital, Brown University Health, Providence, RI, USA.
Mike PayneCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA.
Ellen SeeCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA.
Chia Jung LiRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Eunice LimRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Yasin AbulDivision of Geriatrics and Palliative Medicine, Rhode Island Hospital, Brown University Health, Providence, RI, USA.
Clare NugentDivision of Geriatrics and Palliative Medicine, Rhode Island Hospital, Brown University Health, Providence, RI, USA.
Alejandro B BalazsRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Jürgen BoschCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA.
Christopher L KingCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA.
Brigid WilsonGeriatric Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA.
Stefan GravensteinDivision of Geriatrics and Palliative Medicine, Rhode Island Hospital, Brown University Health, Providence, RI, USA.
David H CanadayDivision of Infectious Diseases and HIV Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0001-5503-7888

Funding

Non-inferiority study of adjuvanted vs. high dose flu vaccine in residents of long term careR01AI129709 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI CANADAY, DAVID H, GRAVENSTEIN, STEFAN · 2018 to 2021
$4.7M
Early Drivers of Humoral Immunity to SARS-CoV-2 InfectionsU01CA260539 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KING, CHRISTOPHER L · 2020 to 2024
$3.4M
NCI NIH HHS U01 CA260539NIAID NIH HHS R01 AI129709
6 · The paper itself

Abstract

Nursing home residents (NHRs) remain among the most vulnerable to severe outcomes from SARS-CoV-2 infection. While mRNA-1273 (Spikevax, Moderna) and BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccines are widely used in this population, comparative data on their immunogenicity, particularly after bivalent boosters, remain limited. We conducted a longitudinal immunologic evaluation of U.S. NHRs who received either the mRNA-1273 or BNT162b2 bivalent vaccine. Serum samples were collected 10-30 d post-vaccination. Anti-spike IgG levels were measured using a Luminex bead-based assay, and neutralizing titers were assessed via pseudovirus neutralization. Comparative analyses of the titer distributions were performed using two-sided Wilcoxon rank-sum tests. Both vaccine groups demonstrated strong humoral responses to the ancestral Wuhan strain and Omicron BA.4/5 subvariants. Spike-binding antibody levels and neutralization titers were comparable between the mRNA -1273 and BNT162b2 vaccine formulations. Conclusions: Both mRNA-1273 and BNT162b2 mRNA vaccines elicit similarly robust humoral immunity in NHRs, supporting their interchangeable use in booster strategies. Our findings underscore the importance of timely booster administration over exact product selection in protecting this high-risk, immunosenescent population.

Indexed as

2019-nCoV Vaccine mRNA-1273COVID-19COVID-19 VaccinesImmunogenicity, VaccineSARS-CoV-2AgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineFemaleHumansImmunization, SecondaryImmunoglobulin GLongitudinal StudiesMale2019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GCOVID-19immunizationimmunogenicityimmunologylong-term caremRNA vaccinenursing homepreventionSARS-CoV-2vaccines

Identifiers

PMID42551467
PMCPMC13471111

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.